Acute liver failure (ALF) is a severe life-threatening disease which usually arises in patients with-irreversible liver illnesses. Although human ectonucleotide triphosphate diphosphohydrolase-1, E-NTPDase1 (CD39) and ecto-5′-nucleotidase, Ecto5′NTase (CD73) are known to protect tissues from ALF, the expression and function of CD39 and CD73 during ALF are currently not fully investigated. We tested whether CD39 and CD73 are upregulated by hypoxia inducible factor (HIF)-1α, and improve ischemic tolerance to ALF. To test our hypothesis, liver biopsies were obtained and we found that CD39 and CD73 mRNA and proteins from human specimens were dramatically elevated in ALF. We investigated that induction of CD39 and CD73 in ALF-related with wild type mice. In contrast, deletion of cd39 and cd73 mice has severe ALF. In this study, we concluded that CD39 and CD73 are molecular targets for the development of drugs for ALF patients care.
Introduction
Hepatic diseases caused by viruses or toxins lead to massive apoptosis and necrosis in hepatocytes which ultimately cause fatal liver failure. These liver diseases are remaining critical health issues with significant morbidity and mortality (Liaw et al., 2004) . In addition, the liver diseases are increasing the need for urgent transplantation -an unsustainable situation because of the severe shortage of donor livers. Thus, there is an urgent need to develop novel hepatoprotective agents to cure hepatic diseases. One experimental tool widely used to identify hepatoprotective agents is thioacetamide (TAA, 100 μg/g). TAA-induced acute liver failure (ALF) is considered to be a typical model because it mimics many aspects of human liver diseases, and is widely used as an experimental tool to identify hepatoprotective agents (Reif et al., 2004) .
ALF is known to accompany severe hypoxia in the liver. Under hypoxic conditions, hypoxia-inducible factor (HIF)-1α, that regulates gene expression including hypoxia-associated anti-inflammatory responses, acts as a master transcription factor (Khoury et al., 2007; Rosenberger et al., 2009; Tak et al., 2011) . HIF-1α is an important modulator of oxygen homeostasis, anti-inflammatory responses, and protective -signaling pathways of various tissues. (Curtis et al., 2015; Rosenberger et al., 2009; Tak et al., 2011; Zimmerman et al., 2013b) . HIF-1α adjusts the signaling properties of extracellular adenosine and the production (Eckle et al., 2014; Grenz et al., 2012; Tak et al., 2011) . HIF-1α, in particular, -adjusts induction of CD73 (Hart et al., 2008b; Synnestvedt et al., 2002) and extracellular production of adenosine and A2B adenosine receptor (A2BAR) (Zimmerman et al., 2013a) .
Based on these data, we investigated the roles and specific mechanisms of action of CD39 and CD73 in TAA-induced ALF in mice. Laboratory investigations and studies in genetic mouse models have implicated extracellular adenosine in dampening hypoxia-induced inflammation-such as occurs during liver failure. Adenosine dominantly prohibits from ATP conversion and ADP in the extracellular case.
Our data provide strong evidence that CD39 and CD73 could effectively prevent and treat TAA-induced liver injury, which may be mediated by up-regulation of HIF-1α. In additional studies, we correlated changes in the expression of CD39 and CD73 with expressional studies of mice undergoing liver failure and functional studies in mice with genetic deletion of cd39 or cd73. Toxicology and Applied Pharmacology 314 (2017) 72-81 Abbreviations: ALF, acute liver failure; HIF-1α, hypoxia inducible factor-1α; CD39, ecto-5′-nucleotidase 39; CD73, ecto-5′-nucleotidase 73.
⁎ Technologies) and Chang cell (CCL-13™, ATCC, Rockville, MD, USA) was grown in Dulbecco's Modified Eagles Medium (DMEM; HyClone Laboratories, Logan, UT, USA) supplemented with 10% fetal bovine serum (FBS; Corning Life Sciences, Tewksbury, MA, USA) and 100 units/ml penicillin, and 100 μg/ml streptomycin (HyClone Laboratories). For hypoxic experimental culture condition, HepaRG and Chang cells were grown in the hypoxic chamber (MCO-18M; Sanyo, Tokyo, Japan) which has in an air consisting of 94.9% N2, 5% CO2, 0.1% O2 (Dianat et al., 2014; .
RNA interference
Small interfering RNAs (siRNA) specific to either HIF-1α (HIF-1α siRNA) or scrambled sequences (scrambled-siRNA) were prepared by Bioneer Corporation (Daejeon, Republic of Korea). Si-RNA (0.5 μg) was used for transfection using the OmniPORTER transfection reagent (MP biomedicals, Solon, OH, USA) (Tak et al., 2011) and the sequences of siRNA were: HIF-1α siRNA sense, 5′-
anti-sense, 5′-ACGAAAUUGGUGGCGUAGG(dTdT)-3′.
Patient tissue samples
Human liver tissues were obtained from the patients who were diagnosed with ALF. All of the ALF tissue samples, paired with adjacent non-ALF specimens, were obtained by the Asan Medical Center. Sample collection and patients' specimens were allowed by Asan Medical Center Institutional Review Board (AMCIRB) of Asan Medical Center, University of Ulsan College of Medicine, Seoul, and the Republic of Korea.
Animal experiments
We performed animal experiments with these two groups of mice i.e., mice with a cd73-deletion (stock no. 018986; Jackson Laboratory, Bar Harbor, ME, USA) and mice with a cd39-deletion (Enjyoji et al., 1999) .
Induction of ALF
Male mice weighing 20 to 25 g were used as in vivo ALF models. Mice were served with 5 mg DMOG (5 mg intraperitoneal, 4 h prior to ALF, Frontier Scientific, Logan, UT, USA). This chemical is a prolyl-hydroxylase (PHD) inhibitor that can be used to induce ALF under normoxia (Hart et al., 2011; Li et al., 2015) , or 17-DMAG (1 mg intraperitoneal, 4 h prior to ALF, LC Laboratories, Woburn, MA, USA) which is an inhibitor of HIF-1α (Liu et al., 2007) . TAA (100 μg/g) was intraperitoneally injected into WT mice (n = 16). We then we checked the TAAtreated mice for 24 h. The livers from WT mice were sacrificed 24 h after TAA administration to perform liver function tests e.g., assess pathophysiologies. Control mouse was treated with a similar volume of normal saline.
Real-time RT-PCR
Mice were sacrificed and hepatic samples were harvested. Total RNA was extracted with the total NucleoSpin RNA II RNA isolation prep kit, (Macherey & Nagel, Dueren, Germany). Next, cDNA was synthesized by performing a reverse transcription (RT) with a script cDNA Synthesis kit (Bio-Rad, Hercules, CA, USA). For PCR, the primer sets contained 1 μM of each sense and antisense primer with SYBR Green (Molecular Probes, New Brunswick, NJ, USA). Sequences of primer (sense/antisense, respectively) for murine CD73 were 5′-CAA ATC CCA CAC AAC CAC TG-3′ and 5′-TGC TCA CTT GGT CAC AGG AC-3′ and the sequences for CD39 were 5′-AGC AGC TGA AAT ATG CTG GC-3′, 5′-GAG ACA GTA TCT GCC GAA GTC C-3′. Murine GAPDH sense (5′-ACA TTG GCA TGG CTT TGT TT-3′) and antisense (5′-GTT TGC TCC AAC CAA CTG CT-3′) primers were treated with the control template. The mRNA and the fold change in mRNA were detected as written formerly (Eltzschig et al., 2003) .
Immunoblotting experiments
Protein samples were resolved on a 12% polyacrylamide gel and transferred to the membranes. The membranes were blocked with 5% nonfat dry milk (Applichem, Cheshire, CT, USA) in Tris-buffered saline Tween-20 and were incubated with anti-CD73 rabbit polyclonal antibody raised against the C-terminus (expected molecular mass, 63 kDa; Abgent, San Diego, CA, USA); anti-CD39, an affinity-purified goat polyclonal antibody raised against a peptide mapping near the C terminus of CD39 of rat origin (39 kDa; Santa Cruz Biotechnology, Danvers, MA, USA); or HIF-1α antibody (120 kDa; BD Biosciences, San Jose, CA). Membranes were incubated with goat anti-rabbit HRP. Protein signals were detected by ECL. For the loading control, blots were washed and re-probed for actin with a mouse monoclonal anti-human actin primary antibody (CP01, Calbiochem) and a goat anti-mouse secondary antibody (401225, Calbiochem). Washing the membrane was repeated, and proteins were detected by ECL.
Liver histology
Mice left liver lobes were harvested; and liver tissues were fixed in 4.5% buffered formalin, dehydrated, and embedded in paraffin. Sections (3 μm) were stained with hematoxylin and eosin, and the extent of liver damage was quantified. Injury was classified using the following fourpoint scale, in which a numerical score (Suzuki scoring 0-4) was assigned based on the degree of liver damage: 0 = normal; 1 = development of sinusoidal congestion space; 2-3 = presence and/or severity of sinusoidal congestion and cytoplasmic vacuolization; 4 = necrosis of parenchymal cells, and hemorrhage (Hart et al., 2008b) .
Statistical analysis
All statistical analyses were performed using GraphPad Prism 5.0 software for Windows XP (GraphPad Software, La Jolla, CA, USA). Data for the liver injury score are expressed as median and range. All other data are expressed as mean ± SD of 3-8 samples per condition. Each western blotting experiment was repeated three times. Statistical analyses were performed using Student's t-test or one-way analysis of variance (ANOVA) followed by Bonferroni's post hoc test. A value of P b 0.05 was considered statistically significant.
Results

CD39 and CD73 are induced under hypoxic condition in normal hepatocyte
To reveal whether CD39 and CD73 would be increased by hypoxia, we set up human liver hepatocyte HepaRG and Chang to hypoxic conditions in a time-dependent manner up to 12 h. HIF-1α is stabilized dramatically in both the HepaRG and Chang cells. As a result, we predicted CD39 and CD73 proteins also upregulated after 6 h of hypoxic condition exposure and upregulated for up to 12 h (Fig. 1A) . To test the induction of CD39 and CD73 mRNA under hypoxia, we performed RT-PCR. The results showed that the level of CD39 and CD73 are highly increased under hypoxic condition in both HepaRG and Chang cell lines (Fig. 1B) . To study if CD39 and CD73 mRNA could be upregulated by transcriptionally or mRNA in the hypoxic condition, HepaRG and Chang cells were placed under the hypoxic condition and treated with 5 μg/ml of actinomycin D. This was done, to inhibit the de novo synthesis of the CD39 and CD73, for 9 h and placed to normoxia and hypoxia separately for up to 12 h. The half-life of CD39 and CD73 turned out to be similar under both conditions, indicating that CD39 and CD73 mRNA are really regulated at the transcriptional level under hypoxia in both the normal hepatocyte HepaRG and Chang cell lines (Fig. 1C) . The quantitative RT-PCR (qRT-PCR) also showed a significant increase in CD39 and CD73 mRNA levels in hypoxia (Fig. 1D) . These data also showed that CD39 and CD73 mRNA transcriptionally upregulation following hypoxic condition. 
CD39 and CD73 are transcriptionally induced by HIF-1α
CD39 and CD73 were transcriptionally induced under hypoxia, we wondered whether HIF-1α was stabilized in a dose-dependent manner treatment with CoCl2, which is a hypoxia-mimicking agent, and dimethyloxaloylglycine (DMOG) which is a pan-prolylhydroxylase inhibitor that is associated with robust HIF stabilization and induction of HIF-dependent genes in HepaRG and Chang cells ( Fig. 2A left) (Eckle et al., 2008; Aragones et al., 2009; Rosenberger et al., 2009; ). Moreover, we treated pcDNA3-HIF-1α expression vector transfection experiments transiently. That was not changed even under the normoxia (Masson et al., 2001) . And CD39 and CD73 were upregulated with transfected cells under the normoxia, comparing to the cells were treated with the pcDNA3 empty vector (Mock) transfection ( Fig. 2A, right) . Moreover, HIF-1α inhibitors, which are DMAG and deguelin, hypoxia-mediated CD39 and CD73 upregulation (Fig. 2B, left) . As a result, when we treated that HIF-1α siRNA to check endogenous HIF-1α expression level indicates similar patterns like these two inhibitors (Fig. 2B, right) .
Human CD39 and CD73 are upregulated during human hepatic failure
In the present study, we hypothesized that CD39 could dampen liver inflammation during ALF. Real-time PCR was used to assess human hepatic mRNA transcript levels in the samples obtained from liver biopsies of patients diagnosed with ALF were assessed using real-time PCR; each ALF liver had its own control (Fig. 3A) . As shown in Fig. 3B , human CD39 was significantly up-regulated under ALF conditions. Similarly, western blot studies of CD39 protein levels revealed a dramatic increase in CD39 protein following ALF in each patient (n = 5; Fig. 3C ). Taken together, these analyses show for the first time that human ALF is associated with transcriptional upregulation of CD39 and increased protein levels of CD39. Based on our initial findings, we examined the hepatic CD73 expression during ALF. Similar to CD39 expression after ALF, we found significant induction of CD73 transcript levels with RT-PCR relative to GAPDH (Fig. 3D) . Moreover, we also found that CD73 protein levels were markedly elevated in each individual patient following ALF compared with control samples (Fig. 3E) . Taken together, these analyses provide the first experimental evidence that CD73 transcript and protein levels are elevated during human ALF.
Global deletion of CD39 aggravates murine acute liver failure
As a next step, we validated our human findings in a murine model of ALF, which would allow us to perform genetic studies. At first step, we treated hepatotoxic drug TAA and examined cd39/cd73 transcript and protein levels in WT mice. As the data shows, CD39 protein level is increased in TAA-induced ALF in WT mice (Fig. 4A) and densitometry of western blotting of CD39 (Fig. 4B) . And also we found CD39 transcript level is markedly increased (Fig. 4C) . As a next step, we exposed cd39-deficient mice to ALF; we observed significantly increasing in liver injury following TAA treated in cd39 −/− mice. Indeed, mice with genetic deletion for cd39 exposed to hepatic drug TAA showed increasingly high levels of tissue injury as examined by induction in AST (Fig. 4D) and ALT (Fig. 4E) . Additionally, the histologic injury was dramatically worse necrosis in the sections derived from cd39 and cd73 deletions compared to WT mice (Fig. 4F) and quantification of the liver injury measured using the Suzuki histological scoring index (0-4) (Fig. 4G) . representative slides is shown), and histologic tissue injury quantification (G) Suzuki scoring index, 0-4; (n = 4-6). Data presented as mean ± SD of three to eight samples per group. P b 0.05, one-way analysis of variance followed by Bonferroni's multiple comparison tests.
CD73 deletion murine increases acute liver failure
As a next step, we tried to validate our human findings in the murine model of ALF, which would allow us to perform genetic studies. We treated hepatotoxic drug TAA and examined cd73 protein level (Fig. 5A ) in WT mice and quantification of protein levels (Fig. 5B) . And we also found CD73 transcript level is highly induced in TAA treated WT mice (Fig. 5C) . As a next step, we exposed cd73 deficient mice to ALF; we observed significantly increasing in liver injury following TAA treated in cd73 −/− mice. Indeed, mice with genetic deletion for cd73 exposed to hepatic drug TAA showed increasingly high levels of tissue injury as examined by induction in AST (Fig. 5D ) and ALT (Fig. 5E) . Additionally, the histologic injury showed dramatically increased necrosis in the sections derived from cd73 deletions compared to WT mice ( Fig. 5F ) and quantification of the liver injury measured by Suzuki scoring (0-4) (Fig. 5G ).
3.6. DMOG treatment induces HIF-1α protein and CD39 and CD73 mRNA
To address the individual contributions of CD39 and CD73 to ALF, we next performed experiments with the hepatotoxic drug TAA. Mice were treated with TAA and DMOG or DMAG for 3 h. Control mice equal matched by sex, weight and age were anesthetized, and treated with normal saline for 3 h in similar conditions. When we established acute liver injury with TAA and DMOG, HIF-1α was dramatically induced from the control group, especially in DMOG-treated mice. On the other hand, the HIF-1α level was not elevated in the DMAG-treated WT mice (Fig. 6A) . In addition, densitometry showed the same pattern (Fig. 6B) . Moreover, hematoxylin and eosin staining (Fig. 6C ) and histology scoring (Fig. 6D) showed protective effects against ALF in DMOGtreated WT mice compared with DMAG-treated mice. We also tested if CD39 is transcriptionally induced in the drug treated-mouse models and; used real-time RT-PCR to compare CD39 transcript levels. Consistent with previous experiments suggesting that CD39 and CD73 expression is increased in hypoxia mimicking DMOG-treated mice, we found a highly increasing of CD39 and CD73 mRNA levels ( Fig. 6E and F ). Taken together, these studies provided additional pharmacological evidence of HIF-mediated tissue protection during acute liver failure.
Discussion
Previous studies have implicated extracellular adenosine generation via the CD39 and CD73 pathway in organ ischemia reperfusion injury (Eckle et al., 2007; Eltzschig et al., 2003; Eltzschig et al., 2004; Hart et al., 2008a; Hasegawa et al., 2008; Reutershan et al., 2009 ). However, the relevance of this pathway-and the transcriptional regulation of both enzymes during human ALF have been unclear. In our current study, we hypothesized that human CD39 and CD73 are transcriptionally induced during human ALF-as part of an endogenous feedback loop that dampens hypoxia-induced inflammation of the liver.
In our current analyses, we found that DMOG treatment prior to TAA induction of the ALF condition induced HIF-1α protein and, CD39 and CD73 mRNA levels in WT mice but was blocked in DMAG-treated WT mice. Even though we did not admeasure other transcriptional pathways, a lot of lines of evidence connote hypoxia-dependent-pathways in this adenine nucleotide to adenosine metabolism, as well as amplification of adenosine receptor-signaling events in the presence of limited oxygen availability (Ledoux et al., 2003; Linden, 2001; Montesinos et al., 2002; Narravula et al., 2000; Semenza, 1999) .
To test this hypothesis and to advance this line of research in a translational direction, we performed a current clinical study to examine the effectiveness of human ALF on the human CD39 and CD73 expression. We indeed observed that human CD39 and CD73 mRNA levels were increased following ALF from the human samples. In addition, studies in cd39 −/− or cd73 −/− mice suggest that the expressional increases in both enzymes promote liver protection, as both knockout mouse lines were significantly more prone to hepatic failure. Taken together, our current findings indicate that CD39 and CD73 are transcriptionally induced by HIF-1α while protecting the liver from human ALF. Two previous studies have reported that the transcript levels of murine CD39 and CD73 are transcriptionally increased during ischemic preconditioning (Eckle et al., 2007; Hart et al., 2008b) . As such, these studies implicate the CD39-and CD73-dependent production of extracellular adenosine in the protective effects to the tissue of ischemic preconditioning. Interestingly, previous studies have indicated two distinct pathways for CD39 or CD73 induction during the limited oxygen condition, such as during hepatic ischemic condition. Indeed, analyses with the promoter constructs and luciferase assays strongly show the HIF-1α in the transcriptional induction of CD39 and CD73 (Synnestvedt et al., 2002) . Taken together with our present results showing human CD39 and CD73 induction during human ALF, these findings suggest that hypoxia-elicited transcriptional pathways mediate CD39 and CD73 induction during human ALF. Our present study findings suggest that CD39 and CD73 are induced as part of an endogenous protective pathway that is activated during human ALF. It remains unclear which adenosine receptors mediate the liver protective effects of adenosine during ALF. Previous studies have found that the Adora2b receptor plays important functional roles in dampening hypoxia-induced inflammation (Eckle et al., 2014; Tak et al., 2011) .
In conclusion, CD39 and CD73 transcription is induced during ALF in humans, a finding that correlates with an increased susceptibility of DMOG-and DMAG-treated murine models of human ALF to hepatic injury. As such, our current findings implicate CD39 and CD73 induction in an endogenous protective pathway for hypoxia-elicited increases in nucleotide phosphohydrolysis and adenosine signaling and the present studies indicate that CD39 and CD73 transcript levels are induced during acute liver failure in humans, a finding that correlates with an upregulated these cd39
−/− and cd73 −/− mice susceptibility to liver failure in mouse models of hepatic failure. Thus, these findings in patients undergoing ALF represent an important step in the translation of pharmacologic concepts and approaches from the bench to the bedside. Ultimately, they support the use of adenosine receptor agonists (e.g. for Adora2a or Adora2b), or an indirect means of pharmacologically enhancing extracellular signaling to prevent ALF.
